Welcome to our dedicated page for Thermo Fishr Sci news (Ticker: TMO), a resource for investors and traders seeking the latest updates and insights on Thermo Fishr Sci stock.
Thermo Fisher Scientific Inc. (NYSE: TMO) is frequently in the news as the world leader in serving science, with disclosures and press releases covering its activities across life sciences, diagnostics, analytical instruments and pharma services. News about Thermo Fisher often highlights how the company’s technologies and services support customers in accelerating life sciences research, solving analytical challenges, improving laboratory productivity, enhancing diagnostics and enabling the development and manufacture of life‑changing therapies.
Recent Thermo Fisher news includes strategic collaborations, regional investments, product clearances, capital allocation decisions and financing transactions. The company announced a collaboration with NVIDIA to power AI‑based solutions and laboratory automation, pairing its scientific instruments and lab software with NVIDIA’s AI infrastructure to increase automation, accuracy and speed in laboratories. It also reported an expansion of its bioprocessing capabilities in Asia through Bioprocess Design Centers in Incheon, Hyderabad and Singapore, aimed at supporting the region’s biopharmaceutical industry.
Thermo Fisher’s news flow also covers regulatory and clinical milestones, such as 510(k) clearance in the United States for the EXENT System, an automated platform designed as an aid in the diagnosis of multiple myeloma and related disorders. Financial and corporate updates include announcements of euro‑denominated and U.S. dollar‑denominated senior note offerings, a $5 billion share repurchase authorization, quarterly dividends, and agreements and completions related to acquisitions such as Solventum Corporation’s purification and filtration business and Clario Holdings, Inc.
Visitors to this TMO news page can review a stream of these company‑specific developments, from earnings‑related announcements and conference presentations to leadership changes and strategic initiatives disclosed in press releases and SEC‑linked communications.
Thermo Fisher Scientific (TMO) reported strong financial results for Q4 and full-year 2021. Q4 revenue hit $10.70 billion, with diluted EPS at $4.17 and adjusted EPS at $6.54. For the full year, revenue surged 22% to $39.21 billion, with GAAP EPS increasing 22% to $19.46. The company achieved $9.23 billion in COVID-19 response revenue and invested $2.5 billion to enhance capacity. In acquisitions, TMO deployed $24 billion, including PPD, Inc., and PeproTech, while committing to net-zero carbon emissions by 2050.
Thermo Fisher Scientific (NYSE:TMO) has completed its acquisition of PeproTech for approximately $1.85 billion on December 30, 2021. PeproTech specializes in recombinant proteins such as cytokines and growth factors, which are integral to cell and gene therapy development. This acquisition enhances Thermo Fisher's biosciences portfolio, allowing for improved offerings to pharma and biotech clients. CEO Marc Casper highlighted that the integration will leverage existing capabilities and foster growth in the expanding cell therapy market.
Thermo Fisher Scientific (NYSE: TMO), a leader in scientific services, will have CEO Marc N. Casper present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 8:15 a.m. (EST). The presentation will cover the company's business outlook and future financial expectations. Thermo Fisher reported annual revenues of approximately $40 billion and employs over 100,000 people globally. Investors can access the webcast via the company's website.
Thermo Fisher Scientific (NYSE: TMO) announced the release of its fourth quarter and full year 2021 financial results on February 2, 2022, before market opening. The earnings call will take place at 8:30 a.m. EST on the same day. Investors can listen in via phone or the company's website. Thermo Fisher is a leader in the science sector with annual revenues around $40 billion. The company aims to support customers in various fields, including life sciences and diagnostics, with an extensive range of innovative technologies and services.
Thermo Fisher Scientific (NYSE: TMO), a leader in serving science, announced that Marc N. Casper, its CEO, will present at the 2022 Goldman Healthcare CEOs Unscripted Conference on January 6, 2022, at 9:00 a.m. EDT. This virtual event will highlight the company's initiatives in the healthcare sector. With an annual revenue of approximately $40 billion, Thermo Fisher supports various industries, including life sciences and diagnostics, through its innovative technologies and services. For more details, visit thermofisher.com.
Thermo Fisher Scientific has finalized its acquisition of PPD, Inc. for $17.4 billion, enhancing its position in the biopharma and biotech sectors. The acquisition is expected to add $1.50 to Thermo Fisher's adjusted earnings per share in 2022 and generate approximately $125 million in total synergies within three years. With this integration, Thermo Fisher expands its service offerings across clinical development, covering scientific discovery to drug manufacturing. PPD's stock has ceased trading on Nasdaq as it becomes part of Thermo Fisher's Laboratory Products and Services Segment.
BioGX announced that its SARS-CoV-2 diagnostic portfolio can detect the Omicron variant (B.1.1.529). The surveillance program includes in-silico analyses confirming detection across all variants of interest. BioGX's COVID-19 RT-PCR tests are compatible with several real-time PCR platforms, notably the Xfree COVID-19 Direct RT-PCR, which is FDA authorized for multiple specimen types. This test offers extraction-free options, enhancing workflow efficiency. BioGX operates under ISO 13485 standards, providing over 60 multiplex real-time PCR products worldwide.
Thermo Fisher Scientific (NYSE:TMO) confirmed that its TaqPath COVID-19 tests accurately detect the Omicron variant, ensuring reliable results despite the variant's mutations. The tests, which target three gene regions, remain unaffected in accuracy due to the unaffected orf1a/b and N gene targets. New TaqPath COVID-19 2.0 tests utilize eight gene targets to detect SARS-CoV-2 effectively. This capability is crucial for tracking the Omicron variant's spread and supporting global pandemic response efforts.
Thermo Fisher Scientific (NYSE:TMO) announced its plan to redeem Senior Notes totaling approximately $2.2 billion on December 3, 2021. The redemption includes $1.1 billion of 4.133% Senior Notes due 2025 and $1.1 billion of 4.497% Senior Notes due 2030. Investors will receive the greater of the principal amount or the present value of remaining scheduled payments, plus accrued interest. The company will fund the redemption using cash on hand. This move highlights the firm's commitment to managing its debt effectively.
Thermo Fisher Scientific (NYSE: TMO) has priced a €2.8 billion offering of euro-denominated senior notes, which includes €1.7 billion in floating rate notes, €550 million in 0.000% senior notes due 2023, and €550 million in sustainability notes due 2025. The offering is expected to close around November 18, 2021. Proceeds will be used to support the acquisition of PPD, Inc. and for general corporate purposes. The sustainability notes aim to fund eligible green projects. The offering complies with SEC regulations and is targeted at professional investors.